WebJul 5, 2024 · Per the terms, Syros ( SYRS) will issue ~74.3M shares of its common stock to TYME investors, and TYME stockholders are entitled to nearly 0.4312 shares of Syros ( SYRS) common stock for... WebTYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles.

TYME Technologies (@tyme_inc) / Twitter

WebSep 15, 2024 · Syros Pharmaceuticals, Inc. SYRS, a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. TYME today announced the results of the special ... WebJul 5, 2024 · Rare Daily Staff Syros Pharmaceuticals, a company focused on the development of medicines that control the expression of genes will acquire Tyme Technologies, a company developing cancer metabolism-based therapies with low toxicity profiles. Syros will acquire Tyme’s assets and net cash at closing, which after accounting … lee holdmann attorney

Tyme Technologies - Overview, News & Competitors

WebSep 15, 2024 · Syros and Tyme Technologies Announce Stockholder Approval of Merger TYME Technologies, Inc. September 15, 2024, 4:13 PM · 10 min read TYME Technologies, … WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement SYRS July 5, 2024 Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 … WebAug 9, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. lee holden breathwork